Source link : https://www.newshealth.biz/health-news/do-benefits-still-outweigh-risks/
Reports of a small number of patients developing secondary T-cell malignancies following treatment with chimeric antigen receptor (CAR) T-cell immunotherapy have raised concerns and prompted a class-wide boxed warning to the labeling of the therapies by the US Food and Drug Administration (FDA), but for now experts underscore that the benefits of the groundbreaking therapies […]
Author : News Health
Publish date : 2024-02-15 05:06:44
Copyright for syndicated content belongs to the linked Source.
Categories